Literature DB >> 7705400

Regulation of the interaction between Th1 and Th2 T cell clones to provide help for antibody production in vivo.

L V Rizzo1, R H DeKruyff, D T Umetsu, R R Caspi.   

Abstract

On the premise that an individual with an intact immune system has the capability to develop both cellular and antibody immune responses supported by the balance between the lymphokines secreted by T helper (Th) cells, we studied the interaction between different types of Th cell clones in vivo and the parameters that may affect this interaction. We used an adoptive transfer system in which nude or lethally irradiated mice were reconstituted with histocompatible CD4+ keyhole limpet hemocyanin (KLH)-specific T cell clones with defined lymphokine profiles. This approach allowed us to study the effects of the cognate interaction between T and B cells in the presence of a defined set of lymphokines. We demonstrated that the co-transfer of both subsets of Th cells resulted in increased production of IgA, and decreased production of IgE and IgG2a. The concomitant presence of both cell types also increases their functional survival in vivo. We have shown that in the presence of a Th2 clone, higher immunization doses (above 100 micrograms trinitrophenol (TNP)-KLH/mouse) result in increased production of IgE and IgG1. In contrast, when a Th1 clone is present, low immunization doses (less than 50 micrograms TNP-KLH/mouse) resulted in increased production of IgG2a. We were also able to show that the neutralization of interleukin-4(IL-4) and or interferon-gamma (IFN-gamma) was sufficient to abrogate most of the regulatory effects caused by the Th2 or the Th1 clone respectively. Our results indicate that the subset of T cell(s) transferred determines the type of response obtained. In addition, the data presented indicate that the antigen dose used for immunization can modulate the quantitative parameters of the response. Furthermore, we have shown that the interaction between the two subsets of T cells in vivo is characterized by both antagonistic and agonistic effects and that most of the regulatory effects exerted by one subset over the other are mediated by IL-4 or IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705400     DOI: 10.1002/eji.1830250312

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.

Authors:  R K Agarwal; Y Kang; E Zambidis; D W Scott; C C Chan; R R Caspi
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms.

Authors:  Sabita Rana; Linda Joanne Rogers; Gary Mark Halliday
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

3.  Modulation of delayed-type hypersensitivity during the time course of immune response to a protein antigen.

Authors:  J F Jacysyn; I A Abrahamsohn; M S Macedo
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

4.  Functional analysis of antibody responses of feedlot cattle to bovine respiratory syncytial virus following vaccination with mixed vaccines.

Authors:  K West; J Ellis
Journal:  Can J Vet Res       Date:  1997-01       Impact factor: 1.310

5.  Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells.

Authors:  Phyllis B Silver; Rajeev K Agarwal; Shao-Bo Su; Isabelle Suffia; Rafael S Grajewski; Dror Luger; Chi-Chao Chan; Rashid M Mahdi; John M Nickerson; Rachel R Caspi
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

6.  Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells.

Authors:  Lizette M Cortes; Dody Avichezer; Phyllis B Silver; Dror Luger; Mary J Mattapallil; Chi-Chao Chan; Rachel R Caspi
Journal:  J Leukoc Biol       Date:  2008-05-21       Impact factor: 4.962

7.  Development of CD4+ T cell lines that suppress an antigen-specific immune response in vivo.

Authors:  L Vieira de Moraes; B Sun; L V Rizzo
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

8.  Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation.

Authors:  G Hansen; G Berry; R H DeKruyff; D T Umetsu
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

9.  Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis.

Authors:  T K Tarrant; P B Silver; J L Wahlsten; L V Rizzo; C C Chan; B Wiggert; R R Caspi
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

10.  Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge.

Authors:  T R Johnson; J E Johnson; S R Roberts; G W Wertz; R A Parker; B S Graham
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.